The increased bone remodeling and the metabolic changes (systemic and in the tumor) that follow the drop in estradiol levels (Khosla et al, 2012) may also contribute to the role of RANK as a marker of poor survival after menopause. Here, TNFRSF11A is linked to neoplasm.